Association of gut microbiome with immune status and clinical response in solid tumor patients who received on anti-PD-1 therapies.

Fukuoka, Shota; Motooka, Daisuke; Togashi, Yosuke; Sugiyama, Eri; Udagawa, Hibiki; Kirita, Keisuke; Kamada, Tetsuo; Kawazoe, Akihito; Goto, Kōichi; Doi, Toshihiko; Shitara, Kohei; Nakamura, Shota; Nishikawa, Hiroyoshi

doi:10.1200/jco.2018.36.15_suppl.3011

Cited by 16 publications

(16 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accumulating data indicates that tumor responses to chemotherapies such as gemcitabine [ 38 ] and cyclophosphamide [ 126 ] depend on the gut microbiome. Several studies have shown a correlation between the gut microbiome composition and diversity and the efficacy of immunotherapy in patients with different tumor types, including melanoma, renal clear cell carcinoma, and lung cancer [ 4 , 15 , 17 , 127 , 128 , 129 , 130 ]. Recent data from melanoma patients revealed that the administration of stools from responders to immune checkpoint inhibitors (ICI) to non-responders can revert the primary resistance to these agents and lead to increased tumor infiltration by CD8 T cells [ 131 ], as previously suggested in pre-clinical studies [ 127 ].…”

Section: Microbiome and Antitumor Immunitymentioning

confidence: 99%

Tumor-Associated Microbiome: Where Do We Stand?

Oliva

Mulet-Margalef

Olza

et al. 2021

IJMS

View full text Add to dashboard Cite

The study of the human microbiome in oncology is a growing and rapidly evolving field. In the past few years, there has been an exponential increase in the number of studies investigating associations of microbiome and cancer, from oncogenesis and cancer progression to resistance or sensitivity to specific anticancer therapies. The gut microbiome is now known to play a significant role in antitumor immune responses and in predicting the efficacy of immune-checkpoint inhibitors in cancer patients. Beyond the gut, the tumor-associated microbiome—microbe communities located either in the tumor or within its body compartment—seems to interact with the local microenvironment and the tumor immune contexture, ultimately impacting cancer progression and treatment outcome. However, pre-clinical research focusing on causality and mechanistic pathways as well as proof-of-concept studies are still needed to fully understand the potential clinical utility of microbiome in cancer patients. Moreover, there is a need for the standardization of methodology and the implementation of quality control across microbiome studies to allow for a better interpretation and greater comparability of the results reported between them. This review summarizes the accumulating evidence in the field and discusses the current and upcoming challenges of microbiome studies.

show abstract

Section: Microbiome and Antitumor Immunitymentioning

confidence: 99%

Tumor-Associated Microbiome: Where Do We Stand?

Oliva

Mulet-Margalef

Olza

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…As to the composition differences between microbiomes from responders vs. non-responders, the authors reported the Ruminococcaceae family and the Faecalibacterium genus as the most prevalent among responders, in contrast to species from the Bacteroidales order, which were abundant in the stools of ICI non-responders [10]. This and other studies (Chaput et al, 2017 [38]; Fukuoka et al, 2018 [39]; Maia et al, 2018 [40]) reporting an association between ICI efficacy and gut microbiome composition are presented in Table 1. On the other side, as a drug class that strongly influences the gut's microbial composition, antibiotics are righteously accused of interfering with ICI efficacy.…”

Section: Immune Checkpoint Inhibitors In Regard To Microbiome and Antmentioning

confidence: 76%

Antibiotic-Related Changes in Microbiome: The Hidden Villain behind Colorectal Carcinoma Immunotherapy Failure

Velikova

Krastev²,

Lozenov

et al. 2021

IJMS

View full text Add to dashboard Cite

The interplay between drugs and microbiota is critical for successful treatment. An accumulating amount of evidence has identified the significant impact of intestinal microbiota composition on cancer treatment response, particularly immunotherapy. The possible molecular pathways of the interaction between immune checkpoint inhibitors (ICIs) and the microbiome can be used to reverse immunotherapy tolerance in cancer by using various kinds of interventions on the intestinal bacteria. This paper aimed to review the data available on how the antibiotic-related changes in human microbiota during colorectal cancer (CRC) treatment can affect and determine ICI treatment outcomes. We also covered the data that support the potential intimate mechanisms of both local and systemic immune responses induced by changes in the intestinal microbiota. However, further better-powered studies are needed to thoroughly assess the clinical significance of antibiotic-induced alteration of the gut microbiota and its impact on CRC treatment by direct observations of patients receiving antibiotic treatment.

show abstract

“…47 Two additional Japanese studies performed 16S rRNA gene sequencing of fecal materials from NSCLC (n = 70) and NSCLC (n = 14) as well as gastric cancer (n = 24) patients confirmed that higher diversity of the bacterial community and enrichment of the Ruminococcaceae and Clostridiales order predicted benefit to PD-1 blockade. 38,48 Furthermore, the relative abundance of members of the Ruminococcaceae family 48 correlated with the density of PD-1 + CD8 + T cells among (TILs). Again, another report analyzing the gut microbiota composition from 17 NSCLC patients revealed that Lactobacillus, Clostridium, and Syntrophococcus were overrepresented in R, while Bilophila or Sutterella 49 was dominant in NR.…”

Section: Gut Oncomicrobiota Signatures Associated With Response To Icismentioning

confidence: 99%

Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors

et al. 2020

View full text Add to dashboard Cite

Accumulating evidence from preclinical studies and human trials demonstrated the crucial role of the gut microbiota in determining the effectiveness of anticancer therapeutics such as immunogenic chemotherapy or immune checkpoint blockade. In summary, it appears that a diverse intestinal microbiota supports therapeutic anticancer responses, while a dysbiotic microbiota composition that lacks immunostimulatory bacteria or contains overabundant immunosuppressive species causes treatment failure. In this review, we explore preclinical and translational studies highlighting how eubiotic and dysbiotic microbiota composition can affect progression-free survival in cancer patients.

show abstract

Association of gut microbiome with immune status and clinical response in solid tumor patients who received on anti-PD-1 therapies.

Cited by 16 publications

References 0 publications

Tumor-Associated Microbiome: Where Do We Stand?

Tumor-Associated Microbiome: Where Do We Stand?

Antibiotic-Related Changes in Microbiome: The Hidden Villain behind Colorectal Carcinoma Immunotherapy Failure

Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors

Contact Info

Product

Resources

About